Physician profile
Kyle Lambert
NPI 1225608490
$2,725.95
in general payments reported to CMS, 2019-2025
33 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $340 · 2022: $1,401 · 2023: $633 · 2024: $155 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $370.15 | 2021-2023 | Rybelsus, Wegovy |
| Idorsia Pharmaceuticals US INC | $321.87 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $187.26 | 2021-2025 | Zepbound, Emgality, Jardiance |
| Dexcom, INC. | $159.08 | 2022-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $152.24 | 2021-2023 | Spravato |
| Ultragenyx Pharmaceutical INC. | $125.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $119.06 | 2021-2022 | |
| Astellas Pharma US INC | $112.79 | 2022-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $108.82 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $105.53 | 2022 | |
| Novartis Pharmaceuticals Corporation | $105.16 | 2022 | |
| Axsome Therapeutics, INC. | $100.76 | 2025 | Sunosi |
| Glaxosmithkline, LLC. | $99.65 | 2023 | Arexvy |
| Jazz Pharmaceuticals INC. | $86.64 | 2023-2024 | |
| Abbvie INC. | $66.97 | 2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $61.89 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $55.08 | 2021-2023 | Jynarque |
| Avanir Pharmaceuticals, INC. | $54.85 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $44.36 | 2023 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $38.87 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $26.20 | 2024 | Lumryz |
| Bausch Health US, LLC | $23.61 | 2022 | |
| Exact Sciences Corporation | $23.16 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $20.92 | 2022 | |
| Pfizer INC. | $20.50 | 2024 | |
| Insmed, INC. | $20.25 | 2025 | Arikayce |
| Sumitomo Pharma America, INC. | $20.08 | 2023 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $19.75 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.08 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.71 | 2022 | |
| Alkermes, INC. | $14.39 | 2021 | |
| Janssen Biotech, INC. | $13.83 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.